tradmap

GALT Earnings GALECTIN THERAPEUTICS INC

Reported EPS, revenue and net income by fiscal period (SEC EDGAR) — quarterly and annual. Full financials → Chart & overview → Updated

Annual results

Diluted EPS (annual)
-$1 -$0 $0 2020 2021 2022 2023 2024 2025
EPS
Net income (annual)
-$47M -$24M $0 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Net income
Return on equity (annual)
-3418% -178% 3063% 0% 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
ROE

Quarterly results

Diluted EPS (quarterly)
-$1 -$0 $0 Q3 '22 Q2 '23 Q1 '24 Q3 '24 Q2 '25 Q1 '26
EPS
Net income (quarterly)
-$12M -$6M $0 Q3 '23 Q1 '24 Q3 '24 Q1 '25 Q3 '25 Q1 '26
Net income
Return on equity (quarterly)
0% 13% 26% Q3 '23 Q1 '24 Q3 '24 Q1 '25 Q3 '25 Q1 '26
ROE

Reported EPS history

1–24 of 24
Q2 20262026-06-30-0.222026-08-1410-Q
Q1 20262026-03-31-0.082026-05-1510-Q
FY 20252025-12-31-0.482026-03-3110-K
Q3 20252025-09-30-0.402025-11-1410-Q
Q2 20262025-06-30-0.272026-08-1410-Q
Q1 20262025-03-31-0.152026-05-1510-Q
FY 20252024-12-31-0.762026-03-3110-K
Q3 20252024-09-30-0.572025-11-1410-Q
Q2 20252024-06-30-0.392025-08-1410-Q
Q1 20252024-03-31-0.192025-05-1510-Q
FY 20242023-12-31-0.742025-03-3110-K
Q3 20242023-09-30-0.582024-11-1410-Q
Q2 20242023-06-30-0.352024-08-1310-Q
Q1 20242023-03-31-0.192024-05-1510-Q
FY 20232022-12-31-0.652024-03-2910-K
Q3 20232022-09-30-0.472023-11-1310-Q
Q2 20232022-06-30-0.332023-08-1410-Q
Q1 20232022-03-31-0.172023-05-1510-Q
FY 20222021-12-31-0.522023-03-3010-K
Q3 20222021-09-30-0.402022-11-1410-Q
Q2 20222021-06-30-0.262022-08-1510-Q
Q1 20222021-03-31-0.112022-05-1610-Q
FY 20212020-12-31-0.412022-03-3110-K
Q3 20212020-09-30-0.282021-11-1510-Q

Source: SEC EDGAR / XBRL (reported actuals; no consensus estimates). Some issuers (e.g. mortgage REITs, banks) don't report a conventional revenue line, so those charts may be omitted. Informational only — not financial advice.